The FDA revises requirements for levothyroxine products

被引：10

|

作者：

Burman, Kenneth ^{[1
,2
]}

Hennessey, James ^{[3
]}

McDermott, Michael ^{[4
]}

Wartofsky, Leonard ^{[1
,2
]}

Emerson, Charles ^{[5
]}

机构：

[1] Georgetown Univ, Washington, DC 20057 USA

[2] Univ Hlth Sci, Bethesda, MD USA

[3] Harvard Univ, Sch Med, Boston, MA USA

[4] Univ Colorado, Denver, CO 80202 USA

[5] Univ Massachusetts, Worcester, MA 01605 USA

来源：

THYROID | 2008年 / 18卷 / 05期

关键词：

D O I：

10.1089/thy.2008.0109

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：487 / 490

页数：4

相关论文

共 50 条

[1] Regulation: FDA revises postmarketing reporting requirements
Rios, Maribel
Pharmaceutical Technology, 2007, 31 (11)
[2] FDA announces tighter regulation of oral levothyroxine products
不详
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (19) : 2151 - 2151
[3] FDA revises definition of "no residue"
不详
JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2003, 222 (03): : 273 - 273
[4] FDA revises drug broadcast rules
Karen Birmingham
Nature Medicine, 1997, 3 (9) : 940 - 940
[5] US FDA revises labelling for PPIs
Reactions Weekly, 2010, 1304 (1) : 2 - 2
[6] THE FDA REVISES PREGNANCY RISK INFORMATION
Aschenbrenner, Diane S.
AMERICAN JOURNAL OF NURSING, 2015, 115 (03) : 22 - 22
[7] FDA revises drug broadcast rules
不详
NATURE MEDICINE, 1997, 3 (09) : 940 - 940
[8] FDA REVISES PCB TOLERANCES UPWARD
不详
AMERICAN PAPER INDUSTRY, 1973, 55 (02): : 13 - 13
[9] Levothyroxine and FDA bioequivalence ratings
Fox, GN
JOURNAL OF FAMILY PRACTICE, 2005, 54 (02): : 179 - 179
[10] REQUIREMENTS OF THE FDA FOR THE ENVIRONMENTAL ASSESSMENT OF ANIMAL HEALTH PRODUCTS
HALEY, CJ
MATHESON, JC
EIRKSON, CE
JOURNAL OF HAZARDOUS MATERIALS, 1993, 35 (02) : 217 - 228

← 1 2 3 4 5 →